After a weak June quarter (Q1), a recovery led by the domestic formulations business is expected to lead to strong sequential revenue growth for Indian pharma majors. Brokerages believe the pharma business of domestic-focussed firms could see 40 per cent growth on a sequential basis. Analysts at Anand Rathi expect domestic formulations of companies they cover to pick up, aided by restocking after a subdued Q1 on the implementation of the goods and services tax (GST) regime. The brokerage estimates revenue growth of 47 per cent on a sequential basis and 11 per cent over the year-ago period, ...
TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
LOGIN
Not a member yet ? Resister Now
Connect using any below
WHAT YOU GET
On Business Standard Digital
On
Digital
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
Already registered ?